The 4,096-electrode era: where brain-computer interfaces stand today.

For most of its history, the brain-computer interface field was defined by a single device: the 100-channel Utah array, essentially unchanged since the 1990s. That era is over. The defining trend of the past two years is channel-count scaling — and the numbers now move fast enough to feel like the early days of Moore's law.

In April 2024, surgeons at Mount Sinai placed 4,096 electrodes on a living human brain using Precision Neuroscience's Layer 7 Cortical Interface — a world record, and double the previous mark of 2,048 that Precision itself had set. Notably, Layer 7 is a thin-film array that conforms to the cortical surface without penetrating tissue, part of a broader industry shift toward less invasive access to high-resolution neural data. In April 2025, Precision announced FDA 510(k) clearance for the Layer 7 Cortical Interface for recording, monitoring and stimulating electrical activity on the surface of the brain, with implantation durations of up to 30 days.

Bandwidth is scaling alongside channel count. In November 2025, the FDA cleared Paradromics to begin a clinical trial of its fully implantable Connexus device, aimed at restoring communication — as text or synthesized speech — for people with severe paralysis. Paradromics has claimed information transfer rates above 200 bits per second in preclinical work — roughly an order of magnitude beyond classic cursor-control interfaces, and enough to make decoded speech feel conversational rather than laborious. The trial is now under way: the first participant was implanted in June 2026, and in September 2026 Paradromics reported that she had used the system for real-time speech and text communication. The company has not published words-per-minute or accuracy figures.

The application frontier is widening too. Neuralink's Blindsight program — a microelectrode array implanted in visual cortex to restore a form of sight to blind patients — received FDA Breakthrough Device Designation in September 2024, and in May 2025 Neuralink received a second Breakthrough Device Designation, for speech, aimed at restoring communication for people with severe speech impairment. Speech, movement, vision: each is now a live clinical program somewhere in the industry, not a hypothetical.

Our read: the bottleneck is shifting from hardware to decoding. Once thousands of channels are streaming, the question becomes what model turns spikes into intent — and that is fundamentally a machine-learning problem. It's why we treat decoder drift, calibration, and mental privacy as first-class research problems rather than engineering afterthoughts.

Update, November 9, 2026: this article originally described the Paradromics trial only as cleared to begin. We added that its first participant was implanted in June 2026 and used the system for real-time speech, as Paradromics announced in September 2026, along with two milestones the article had omitted: Neuralink's Breakthrough Device Designation for speech (May 2025) and Precision Neuroscience's FDA 510(k) clearance for implantation of up to 30 days (April 2025).